GGrantIndex
← Leaderboards

Stephan Menne

University Of Kansas Medical Center

$2,795,660
Attributed
$6,553,419
Total exposure
4
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY201225
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,553,419 · 4

By mechanism

R01$6,102,744 · 3
R21$450,675 · 1

Top collaborators

Most similar at University Of Kansas Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Hepatocyte

Research focus

HepatocyteChronic Hepatitis BWoodchuckWoodchuck Hepatitis B VirusHepatitis B VirusPharmaceutical PreparationsViralMutantIn VitroVirionIn VivoInfectionAntiviral AgentsKineticsAffectLiverPrimary Carcinoma Of The Liver CellsInhibitor/AntagonistImmune ResponseReportingHepadnaviridaePredispositionAnimal ModelChronic

Grant awards (15)

Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host$800,416
R01 · FY2025 · AI · contact PI
Exploring Hepatitis B Virus PreCore Gene Functions in Woodchucks$196,425
R21 · FY2025 · AI · contact PI
Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host$820,940
R01 · FY2024 · AI · contact PI
Exploring Hepatitis B Virus PreCore Gene Functions in Woodchucks$254,250
R21 · FY2024 · AI · contact PI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$537,218
R01 · FY2018 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$511,927
R01 · FY2017 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$578,621
R01 · FY2016 · AI
Super-infection and virus spread during chronic hepadnaviral infection$319,945
R01 · FY2016 · CA
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$669,728
R01 · FY2015 · AI
Super-infection and virus spread during chronic hepadnaviral infection$319,945
R01 · FY2015 · CA
Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$405,835
R01 · FY2014 · AI
Super-infection and virus spread during chronic hepadnaviral infection$310,347
R01 · FY2014 · CA
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$182,968
R01 · FY2014 · AI
Super-infection and virus spread during chronic hepadnaviral infection$305,320
R01 · FY2013 · CA
Super-infection and virus spread during chronic hepadnaviral infection$339,534
R01 · FY2012 · CA